Genitourinary Cancers | Specialty

Defining Progression in Kidney Cancer

September 8th 2017

Frontline Decisions in Metastatic Kidney Cancer

September 8th 2017

RCC: Resection in Metastatic Disease

September 8th 2017

Risk of Postsurgical Disease Recurrence in RCC

September 8th 2017

Recent Data in the Adjuvant Setting of RCC

September 8th 2017

Molecular Profiling in Renal Cell Carcinoma

September 8th 2017

Heterogeneity of Kidney Cancer

September 8th 2017

Dr. Campbell Discusses the Goals of the New RCC Guidelines

September 8th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the goals of the newly updated guidelines in renal cell carcinoma.

Dr. Choyke on the Importance of Multidisciplinary Care in Prostate Cancer

September 8th 2017

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses the importance of multidisciplinary care in prostate cancer.

Dr. Hammers on Immunotherapy Combinations in Kidney Cancer

September 8th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses combinations with immunotherapy being investigated for patients with kidney cancer.

Dr. Gupta on Evolving Treatments for RCC

September 7th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the CABOSUN trial investigating cabozantinib (Cabometyx) and sunitinib (Sutent) in patients with renal cell carcinoma (RCC).

Dr. Feldman on Study of Active Surveillance in Younger Men With Prostate Cancer

September 6th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses a study of active surveillance in younger men with prostate cancer.

Dr. Rosenberg Discusses the Importance of Clinical Trials in Bladder Cancer

September 6th 2017

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

Dr. Badani on Determining Which Patients With RCC Will Receive Robotic Surgery

September 6th 2017

Ketan K. Badani, MD, professor of urology at Mount Sinai Hospital, discusses how to determine which patient with renal cell carcinoma (RCC) will benefit from robotic surgery.

Dr. Lallas on Understanding Immunotherapy in GU Malignancies

September 6th 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary malignancies.

Pembrolizumab Approved in Europe for Urothelial Carcinoma

September 6th 2017

The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.

Dr. Kaouk on Benefits of Robotic Partial Nephrectomy for RCC

September 1st 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses the benefits of robotic partial nephrectomy for patients with renal cell carcinoma (RCC).

Dr. Campbell Discusses Advancements in Kidney Cancer Management

August 29th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses recent advancements in the management of kidney cancer.

Dr. Nanus on Cytoreductive Nephrectomy for RCC

August 28th 2017

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses cytoreductive nephrectomy for patients with renal cell carcinoma (RCC).

Tivozanib Approved in Europe for Kidney Cancer

August 28th 2017

The European Commission has approved tivozanib for the treatment of patients with advanced renal cell carcinoma.